# OnCo record capillary-leak-syndrome-on-anticancer-drugs (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "capillary-leak-syndrome-on-anticancer-drugs" ;
  schema:name "Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment"@en ;
  schema:alternateName "capillary leak syndrome"@en, "CLS"@en, "vascular leak syndrome"@en, "systemic capillary leak"@en, "tagraxofusp capillary leak"@en, "Elzonris albumin monitoring"@en, "dinutuximab capillary leak"@en, "interleukin-2 capillary leak"@en ;
  schema:description "A few cancer medicines can make the smallest blood vessels leaky, so fluid and protein seep out of the blood into the tissues. The signs are weight gain, swelling, breathlessness and low blood pressure. Teams watch weight, blood pressure and, for some of these medicines, a blood protein called albumin. If signs appear they pause the medicine and treat by that medicine's own rules."@en ;
  schema:url <https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:related <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/protocols/differentiation-syndrome-recognition-and-treatment/>, <https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/>, <https://onco.cc/protocols/crs-grading-and-management/>, <https://onco.cc/protocols/febrile-neutropenia-first-hour/> ;
  onco:drugs <https://onco.cc/drugs/tagraxofusp/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/aldesleukin/> .
